Your session is about to expire
← Back to Search
PANDA-VAC + Pembrolizumab for Lung Cancer (PANDA-VAC Trial)
PANDA-VAC Trial Summary
This trial is designed to see if it is safe to give a new vaccine to people with squamous cell lung cancer or head and neck cancer.
PANDA-VAC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPANDA-VAC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183PANDA-VAC Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently being treated for an infection.I am fully active and can carry on all pre-disease activities without restriction.My doctor thinks pembrolizumab and PANDA-VAC are not suitable for me.I am 18 years old or older.I agree to a biopsy for vaccine study if my cancer shows certain responses after 7 vaccinations.My cancer hasn't worsened significantly on my current immunotherapy treatment.I agree to use birth control during the study.I have enough stored tumor tissue for vaccine creation.You have a history of a weakened immune system from birth.I have had treatment for lung or head and neck cancer, which cannot be cured.I am a man who either had a vasectomy or will use contraception.I agree to give blood samples and use my previous biopsy samples for the study.I have recovered from the side effects of my last cancer treatment.I am willing and able to follow the study's treatment plan and attend all appointments.I have an autoimmune disease treated with medication in the last 2 years.I have not received any live vaccines within 30 days before starting pembrolizumab.I am taking 10mg or more of prednisone daily or similar medications.I have another cancer that is growing and needs treatment.My cancer has spread to my brain.My blood tests show my bone marrow is working well.I have had an organ, bone marrow, or stem cell transplant.The subject has visible tumors that can be measured using specific guidelines.I have HIV, hepatitis C, or active hepatitis B.My cancer is a specific type of lung or head and neck cancer.
- Group 1: PANDA-VAC combined with pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In which medical conditions is Pembrolizumab commonly prescribed?
"Pembrolizumab has been proven to be effective at treating malignant tumours, unresectable melanomas, and microsatellite instability high."
What other exploratory studies have featured Pembrolizumab as a primary variable?
"At present, there are 963 distinct clinical trials concerning pembrolizumab. Of those studies, 122 of them have reached the third phase and can be found in 35772 different locations across the globe; however, Houston is home to a significant portion of these research efforts."
What is the current enrollment capacity for this clinical trial?
"This trial is no longer accepting participants. Initially posted on December 1st, 2022 and last updated October 31st, 2022, this study has since ended its recruitment phase. If you are looking for other opportunities to participate in a clinical trial, there are currently 1944 studies searching for patients with oral squamous cell carcinoma and 963 trials that have open enrollment for Pembrolizumab treatment."
Has Pembrolizumab received a positive evaluation from the U.S. Food and Drug Administration?
"Our analysts at Power graded the safety of Pembrolizumab with a score of 1 because this Phase 1 trial has only limited evidence regarding its efficacy and safety."
Are there any availability for potential participants in this research project?
"Currently, this trial is not searching for any more participants. It was first published on December 1st 2022 and last updated October 31st of the same year. However, if you are looking for other clinical trials that fit your criteria there are 1944 studies for oral squamous cell carcinoma and 963 involving Pembrolizumab actively seeking enrolment at present."
Share this study with friends
Copy Link
Messenger